NASDAQ:MEDP - Medpace Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $121.83
  • Forecasted Upside: -22.67 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$157.54
▼ -0.82 (-0.52%)
1 month | 3 months | 12 months
Get New Medpace Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MEDP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MEDP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$121.83
▼ -22.67% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Medpace in the last 3 months. The average price target is $121.83, with a high forecast of $180.00 and a low forecast of $75.00. The average price target represents a -22.67% upside from the last price of $157.54.
Hold
The current consensus among 5 contributing investment analysts is to hold stock in Medpace. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/14/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/13/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/12/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/10/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/8/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/7/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/5/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/17/2021TruistBoost Price Target$135.00 ➝ $180.00Low
i
2/16/2021Credit Suisse GroupBoost Price TargetOutperform$155.00 ➝ $178.00Low
i
10/2/2020TruistUpgradeHold ➝ Buy$124.00 ➝ $135.00Medium
i
7/29/2020SunTrust BanksBoost Price TargetHold$95.00 ➝ $124.00Medium
i
Rating by Sandy Draper at SunTrust Banks, Inc.
7/28/2020Credit Suisse GroupBoost Price TargetOutperform$92.00 ➝ $114.00High
i
6/8/2020Robert W. BairdUpgradeUnderperform ➝ Neutral$83.00High
i
Rating by Eric Coldwell at Robert W. Baird
5/13/2020Wolfe ResearchDowngradeOutperform ➝ Peer Perform$91.00High
i
4/30/2020SunTrust BanksUpgradeSell ➝ Hold$54.00 ➝ $85.00High
i
Rating by Sandy Draper at SunTrust Banks, Inc.
4/29/2020Credit Suisse GroupLower Price TargetOutperform$105.00 ➝ $92.00High
i
4/20/2020Robert W. BairdDowngradeNeutral ➝ Underperform$77.00Low
i
4/6/2020SunTrust BanksBoost Price TargetSell$46.00 ➝ $54.00High
i
Rating by Sandy Draper at SunTrust Banks, Inc.
3/23/2020Jefferies Financial GroupLower Price TargetHold$93.00 ➝ $75.00Medium
i
3/17/2020SunTrust BanksDowngradeHold ➝ Sell$100.00 ➝ $46.00High
i
Rating by Sandy Draper at SunTrust Banks, Inc.
2/26/2020SunTrust BanksSet Price Target$100.00Medium
i
Rating by Sandy Draper at SunTrust Banks, Inc.
2/25/2020CSFBBoost Price TargetOutperform$91.00 ➝ $99.00High
i
2/25/2020Credit Suisse GroupBoost Price TargetOutperform$91.00 ➝ $99.00High
i
1/27/2020SunTrust BanksDowngradeBuy ➝ Hold$85.00 ➝ $87.00Low
i
Rating by Sandy Draper at SunTrust Banks, Inc.
7/31/2019SunTrust BanksBoost Price TargetBuy$85.00Low
i
7/30/2019Credit Suisse GroupBoost Price TargetOutperform$65.00 ➝ $77.00High
i
4/30/2019Robert W. BairdBoost Price TargetNeutral ➝ Neutral$57.00 ➝ $62.00High
i
4/2/2019Wolfe ResearchInitiated CoverageOutperformHigh
i
10/31/2018SunTrust BanksUpgradeHold ➝ Buy$63.00High
i
9/17/2018SunTrust BanksInitiated CoverageHold ➝ Hold$63.00High
i
7/31/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$42.00 ➝ $49.00High
i
7/31/2018William BlairUpgradeMarket Perform ➝ OutperformHigh
i
Rating by J. Kreger at William Blair
4/20/2018Mitsubishi UFJ Financial GroupReiterated RatingNeutral$40.00Low
i
Rating by J. Twizell at Mitsubishi UFJ Financial Group
4/10/2018Robert W. BairdSet Price TargetHold$35.00High
i
Rating by Eric Coldwell at Robert W. Baird
3/1/2018Jefferies Financial GroupReiterated RatingHold$35.00Low
i
2/28/2018Wells Fargo & CompanyLower Price TargetMarket Perform ➝ Market Perform$38.00 ➝ $35.00Medium
i
2/27/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$41.00 ➝ $42.00High
i
11/1/2017Jefferies Financial GroupBoost Price TargetHold$34.00 ➝ $38.00N/A
i
11/1/2017William BlairDowngradeOutperform ➝ Market PerformN/A
i
Rating by J. Kreger at William Blair
10/31/2017Robert W. BairdBoost Price TargetNeutral$32.00 ➝ $35.00N/A
i
10/17/2017KeyCorpReiterated RatingHoldN/A
i
10/9/2017Robert W. BairdReiterated RatingHold$32.00N/A
i
9/29/2017Raymond JamesInitiated CoverageMkt Perform ➝ Market PerformLow
i
8/2/2017Jefferies Financial GroupReiterated RatingHold$30.00 ➝ $31.00Low
i
6/6/2017Credit Suisse GroupReiterated RatingOutperform$35.00 ➝ $36.00Low
i
5/3/2017Jefferies Financial GroupReiterated RatingHold$35.50 ➝ $25.50Low
i
5/3/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformHigh
i
4/21/2017Jefferies Financial GroupReiterated RatingHold$35.50Low
i
3/29/2017KeyCorpInitiated CoverageOverweight ➝ Overweight$34.00Medium
i
2/28/2017Jefferies Financial GroupReiterated RatingHold$35.50N/A
i
11/7/2016Jefferies Financial GroupReiterated RatingHold$34.00N/A
i
10/4/2016Jefferies Financial GroupReiterated RatingHoldN/A
i
9/6/2016William BlairReiterated RatingOutperformN/A
i
Rating by J. Kreger at William Blair
9/6/2016Wells Fargo & CompanyInitiated CoverageOutperformN/A
i
9/6/2016UBS GroupInitiated CoverageBuy$35.00N/A
i
9/6/2016Robert W. BairdInitiated CoverageNeutral$35.00N/A
i
9/6/2016Jefferies Financial GroupInitiated CoverageHold ➝ Hold$32.50 ➝ $32.50N/A
i
9/6/2016Credit Suisse GroupInitiated CoverageOutperform$35.00N/A
i
(Data available from 3/7/2016 forward)
Medpace logo
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Read More

Today's Range

Now: $157.54
$148.56
$160.94

50 Day Range

MA: $151.52
$132.02
$168.26

52 Week Range

Now: $157.54
$58.72
$177.12

Volume

309,756 shs

Average Volume

212,997 shs

Market Capitalization

$5.63 billion

P/E Ratio

48.18

Dividend Yield

N/A

Beta

1.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Medpace?

The following Wall Street research analysts have issued stock ratings on Medpace in the last year: Credit Suisse Group AG, Jefferies Financial Group Inc., Robert W. Baird, SunTrust Banks, Inc., Truist, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for MEDP.

What is the current price target for Medpace?

6 Wall Street analysts have set twelve-month price targets for Medpace in the last year. Their average twelve-month price target is $121.83, suggesting a possible downside of 22.7%. Truist has the highest price target set, predicting MEDP will reach $180.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $75.00 for Medpace in the next year.
View the latest price targets for MEDP.

What is the current consensus analyst rating for Medpace?

Medpace currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MEDP, but not buy more shares or sell existing shares.
View the latest ratings for MEDP.

What other companies compete with Medpace?

How do I contact Medpace's investor relations team?

Medpace's physical mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company's listed phone number is 513-579-9911 and its investor relations email address is [email protected] The official website for Medpace is www.medpace.com.